Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr;167(4):e109-e112.
doi: 10.1016/j.chest.2024.10.048.

A Gain-of-Function Mutation in Mechanistic Target of Rapamycin Results in a Tuberous Sclerosis Complex-Like Manifestation of Parenchymal Lung Disease

Thomas C Bolig  1 , Anjana V Yeldandi  2 , Jane E Dematte  1 , Anthony J Esposito  3
Affiliations
Case Reports

A Gain-of-Function Mutation in Mechanistic Target of Rapamycin Results in a Tuberous Sclerosis Complex-Like Manifestation of Parenchymal Lung Disease

Thomas C Bolig et al. Chest. 2025 Apr.

Abstract

Dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway rarely results in parenchymal lung disease, prototypically multifocal multinodular pneumocyte hyperplasia (MMPH) and lymphangioleiomyomatosis (LAM). Although LAM can occur sporadically, to our knowledge, MMPH has not previously been described independent of tuberous sclerosis complex (TSC), a syndrome caused by germline mutations in the tumor suppressor genes TSC1 or TSC2. We report the case of a man with a history of multiple malignancies who presented with incidental chest imaging findings of innumerable ground-glass nodules and several air-filled cysts, offering a diagnostic challenge. Histopathologic findings on lung biopsy identified nodular foci of pneumocyte hyperplasia with negative Human Melanoma Black-45 staining. Next-generation DNA sequencing of the tissue showed a previously described gain-of-function mutation in MTOR. We propose that this patient's TSC-like pulmonary disease is a direct result of this mutation, a novel finding that underscores the role of Next-generation DNA sequencing in cryptic histopathology.

Keywords: cystic lung disease; lymphangioleiomyomatosis; mTOR; mutifocal multinodular pneumocyte hyperplasia; tuberous sclerosis complex.

PubMed Disclaimer

Conflict of interest statement

Financial/Nonfinancial Disclosures None declared.

References

    1. Panwar V., Singh A., Bhatt M., et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Sig Transduct Target Ther. 2023;8(1):1–25. - PMC - PubMed
    1. Henske E.P., Jóźwiak S., Kingswood J.C., Sampson J.R., Thiele E.A. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2 - PubMed
    1. von Ranke F.M., Zanetti G., e Silva J.L.P., et al. Tuberous sclerosis complex: state-of-the-art review with a focus on pulmonary involvement. Lung. 2015;193(5):619–627. - PubMed
    1. Kobashi Y., Sugiu T., Mouri K., Irei T., Nakata M., Oka M. Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: differentiation from multiple atypical adenomatous hyperplasia. Jpn J Clin Oncol. 2008;38(6):451–454. - PubMed
    1. Grabiner B.C., Nardi V., Birsoy K., et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014;4(5):554–563. - PMC - PubMed

Publication types

MeSH terms

Substances